
BRONCHITOL® SHORTLISTED FOR PRESTIGIOUS ORPHAN DRUG AWARD

Pharmaceutical development company Pharmaxis is pleased to announce that its product for cystic fibrosis, Bronchitol, has been shortlisted for the prestigious UK Prix Galien Orphan Drug Award.

Prix Galien is an internationally-recognised award, providing global recognition for the technical, scientific and clinical research skills necessary to develop innovative medicines. Moreover, it gives pharmaceutical companies the opportunity to have their products scrutinised by some of the UK medical profession's most eminent experts, and to be assessed according to the medical, societal and economic benefits they are likely to provide.

The UK Prix Galien judging team is led by Professor Sir Michael Rawlins, President of the Royal Society of Medicine and, until 2013, founding Chairman of the National Institute of Health and Care Excellence. Professor Rawlins is joined by a panel of influential stakeholders from the UK healthcare system.

"The 2014 Orphan Drug Award promises to be very competitive. This year has seen the highest number of orphan drug entrants – and this is something we are all delighted to see. The increase reflects the growing investment companies are making in this vital area, as well as the steady raft of national policies designed to improve health outcomes for patients with rare diseases," says Alison Currie, Director for Clinical Evidence and Strategy, WG Consulting.

Pharmaxis CEO Gary Phillips said, "We are very pleased that the Prix Galien judging panel has seen fit to shortlist Bronchitol for the Orphan Drug Award. To be recognised in this way highlights the potential benefits associated with the product."

Alongside Bronchitol on the shortlist for the Orphan Drug Award are treatments for pulmonary hypertension, idiopathic pulmonary fibrosis and multiple myeloma. All shortlisted products were launched or granted a new indication in the UK between 1st January 2012 and 31st March 2014. The winners will be announced on Wednesday 1st October during a ceremony at the House of Commons, London.

Bronchitol is a precision spray-dried form of mannitol, delivered to the lungs by a specially designed, portable inhaler. The product is approved for cystic fibrosis patients aged over six years in Australia and for patients aged 18 years and over throughout the European Union.

#ENDS#

SOURCE: Pharmaxis Ltd, Sydney, Australia

CONTACT: Felicity Moffatt, phone +61 418 677 701 or email felicity.moffatt@pharmaxis.com.au

About the Prix Galien Awards

The Prix Galien was created in France by pharmacist Roland Mehl, whose aim was to promote the country's significant advances in pharmaceutical research. Until the establishment of the Prix Galien, this discipline remained unrecognised. Mehl brought together an eminent jury consisting of clinicians, toxicologists, pharmacologists and pharmacists to select and honour the most important drugs introduced to the public market and the most significant research teams in the pharmaceutical field. Since then, the Prix Galien has been introduced across Europe and Canada and is now the most prestigious award of its kind in 11 countries. In addition, an International Prix Galien award is given each year, selected from previous winners.

About Pharmaxis

Pharmaxis (ACN 082 811 630) is a specialist pharmaceutical company involved in the research, development and commercialization of therapeutic products for chronic respiratory disorders. Its product Aridol® for the assessment of asthma is sold in key international markets. Its product Bronchitol® for cystic fibrosis is launched in Europe and Australia and its development pipeline of products includes, Bronchitol for other respiratory diseases, PXS64 for the treatment of lung fibrosis, ASM8 for asthma and PXS4728 for fibrotic disease. Pharmaxis is listed on the Australian Securities Exchange (symbol PXS). The company's head office and manufacturing facilities are located in Sydney. For more information about Pharmaxis, go to www.pharmaxis.com.au or contact Investor Relations on phone +61 2 9454 7200.